| Understanding the tumor immune microenvironment (TIME) for effective therapy |
487 |
| High-performance medicine: the convergence of human and artificial intelligence |
390 |
| Mechanisms of NAFLD development and therapeutic strategies |
293 |
| Clinically applicable deep learning for diagnosis and referral in retinal disease |
283 |
| Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning |
222 |
| Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network |
222 |
| Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer's disease |
220 |
| A guide to deep learning in healthcare |
211 |
| Senolytics improve physical function and increase lifespan in old age |
204 |
| Current understanding of the human microbiome |
203 |
| Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study |
192 |
| CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy |
185 |
| Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells |
185 |
| Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma |
183 |
| Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia |
182 |
| End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography |
177 |
| Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab |
174 |
| Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer |
167 |
| Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes |
166 |
| Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction |
166 |
| Phenotype molding of stromal cells in the lung tumor microenvironment |
158 |
| CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade |
155 |
| Clonal replacement of tumor-specific T cells following PD-1 blockade |
150 |
| Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma |
148 |
| Chronic inflammation in the etiology of disease across the life span |
144 |
| CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response |
141 |
| A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments |
137 |
| Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response |
133 |
| Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma |
132 |
| Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus |
126 |
| A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade |
126 |
| Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease |
126 |
| Radiotherapy induces responses of lung cancer to CTLA-4 blockade |
125 |
| Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing |
121 |
| p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells |
119 |
| Clinical-grade computational pathology using weakly supervised deep learning on whole slide images |
117 |
| Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma |
116 |
| Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial |
113 |
| Regional variation limits applications of healthy gut microbiome reference ranges and disease models |
109 |
| Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial |
108 |
| Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease |
107 |
| The practical implementation of artificial intelligence technologies in medicine |
106 |
| An inhibitor of oxidative phosphorylation exploits cancer vulnerability |
102 |
| The vaginal microbiome and preterm birth |
100 |
| Identification of preexisting adaptive immunity to Cas9 proteins in humans |
99 |
| Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer |
99 |
| High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy |
98 |
| The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care |
97 |
| Gut microbiota and intestinal FXR mediate the clinical benefits of metformin |
97 |
| The pros, cons, and many unknowns of probiotics |
97 |
| Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade |
96 |
| Zr-89-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer |
96 |
| Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis |
95 |
| A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells |
95 |
| The microbiome, cancer, and cancer therapy |
94 |
| A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma |
94 |
| Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer |
93 |
| Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis |
93 |
| Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma |
92 |
| Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram |
90 |
| Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia |
89 |
| Protective autophagy elicited by RAF -> MEK -> ERK inhibition suggests a treatment strategy for RAS-driven cancers |
89 |
| Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer |
87 |
| Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma |
85 |
| A cellular census of human lungs identifies novel cell states in health and in asthma |
85 |
| Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography |
84 |
| Somatic mutations precede myeloid leukemia years before diagnosis |
83 |
| High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants |
83 |
| Identifying facial phenotypes of genetic disorders using deep learning |
82 |
| Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer |
82 |
| Biomimetic 3D-printed scaffolds for spinal cord injury repair |
82 |
| Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation |
81 |
| Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study |
80 |
| Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10 |
80 |
| Meta-omics analysis of elite athletes identifies a performance-enhancing microbe that functions via lactate metabolism |
78 |
| An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity |
78 |
| Amyloid-beta plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation |
78 |
| Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer's models |
77 |
| Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer |
77 |
| Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell |
76 |
| Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers |
76 |
| Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons |
75 |
| Genomic correlates of response to immune checkpoint blockade |
74 |
| ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade |
74 |
| Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women |
73 |
| Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma |
72 |
| Metformin reverses established lung fibrosis in a bleomycin model |
72 |
| Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors |
71 |
| Undulating changes in human plasma proteome profiles across the lifespan |
70 |
| The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions |
69 |
| Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination |
69 |
| Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR |
69 |
| A safe and potent anti-CD19 CAR T cell therapy |
66 |
| Disease-specific oligodendrocyte lineage cells arise in multiple sclerosis |
65 |
| Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial |
65 |
| Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia |
65 |
| Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer |
65 |
| Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma |
65 |
| Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency |
64 |
| Single-cell immune landscape of human atherosclerotic plaques |
64 |
| Development of a gut microbe-targeted nonlethal therapeutic to inhibit thrombosis potential |
64 |
| Clinical lessons learned from the first leg of the CAR T cell journey |
63 |
| Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy |
63 |
| Wireless bioresorbable electronic system enables sustained nonpharmacological neuroregenerative therapy |
62 |
| Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase |
61 |
| Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report |
59 |
| Highly efficient therapeutic gene editing of human hematopoietic stem cells |
59 |
| The human heart contains distinct macrophage subsets with divergent origins and functions |
58 |
| Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent |
58 |
| Privacy in the age of medical big data |
58 |
| Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer |
58 |
| H3B- an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers |
57 |
| Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers |
57 |
| Healthy infants harbor intestinal bacteria that protect against food allergy |
56 |
| The landscape of cancer cell line metabolism |
55 |
| Immunogenic neoantigens derived from gene fusions stimulate T cell responses |
55 |
| Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients |
55 |
| High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population |
54 |
| Adrenergic nerve degeneration in bone marrow drives aging of the hematopoietic stem cell niche |
54 |
| Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial |
53 |
| Neuromodulation of lumbosacral spinal networks enables independent stepping after complete paraplegia |
53 |
| Evaluation and accurate diagnoses of pediatric diseases using artificial intelligence |
53 |
| A longitudinal big data approach for precision health |
53 |
| Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma |
52 |
| Treatment of a metabolic liver disease by in vivo genome base editing in adult mice |
52 |
| Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy |
52 |
| Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis |
51 |
| Spinal cord repair: advances in biology and technology |
50 |
| Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate |
50 |
| Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic |
50 |
| Programmable bacteria induce durable tumor regression and systemic antitumor immunity |
50 |
| The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space |
50 |
| A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring |
50 |
| Pericyte degeneration causes white matter dysfunction in the mouse central nervous system |
50 |
| Genome editing in mitochondria corrects a pathogenic mtDNA mutation in vivo |
50 |
| Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models |
49 |
| A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects |
49 |
| Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study |
49 |
| Do no harm: a roadmap for responsible machine learning for health care |
48 |
| Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation |
48 |
| T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant |
48 |
| SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo |
47 |
| A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes |
47 |
| Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector |
46 |
| Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection |
46 |
| Automated deep-neural-network surveillance of cranial images for acute neurologic events |
46 |
| Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals |
46 |
| Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques |
45 |
| Delayed childhood neurodevelopment and neurosensory alterations in the second year of life in a prospective cohort of ZIKV-exposed children |
45 |
| Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(+) diffuse midline gliomas |
45 |
| Healthspan and lifespan extension by fecal microbiota transplantation into progeroid mice |
44 |
| Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1 |
44 |
| ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis |
43 |
| A selective BCL-X-L PROTAC degrader achieves safe and potent antitumor activity |
42 |
| Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma |
42 |
| Farm-like indoor microbiota in non-farm homes protects children from asthma development |
42 |
| Elevated prenatal anti-Mullerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood |
42 |
| Atheroprotective roles of smooth muscle cell phenotypic modulation and the TCF21 disease gene as revealed by single-cell analysis |
41 |
| Microbial network disturbances in relapsing refractory Crohn's disease |
41 |
| Methionine is a metabolic dependency of tumor-initiating cells |
41 |
| Aged blood impairs hippocampal neural precursor activity and activates microglia via brain endothelial cell VCAM1 |
41 |
| Non-invasive prenatal sequencing for multiple Mendelian monogenic disorders using circulating cell-free fetal DNA |
40 |
| Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine |
40 |
| Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome |
40 |
| MitoTALEN reduces mutant mtDNA load and restores tRNA(Ala) levels in a mouse model of heteroplasmic mtDNA mutation |
40 |
| Restorative effects of human neural stem cell grafts on the primate spinal cord |
39 |
| Targeting skeletal endothelium to ameliorate bone loss |
39 |
| De novo NAD(+) biosynthetic impairment in acute kidney injury in humans |
39 |
| Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4 |
39 |
| Microbiota therapy acts via a regulatory T cell MyD88/ROR gamma t pathway to suppress food allergy |
38 |
| STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis |
38 |
| MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency |
38 |
| IFN-gamma-independent immune markers of Mycobacterium tuberculosis exposure |
38 |
| A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment |
37 |
| Nociceptor sensory neurons suppress neutrophil and gamma delta T cell responses in bacterial lung infections and lethal pneumonia |
37 |
| Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells |
37 |
| A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis |
37 |
| The exerkine apelin reverses age-associated sarcopenia |
37 |
| Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer |
37 |
| Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss |
37 |
| Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma |
37 |
| Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses |
37 |
| Identification of rare-disease genes using blood transcriptome sequencing and large control cohorts |
36 |
| ApoE attenuates unresolvable inflammation by complex formation with activated C1q |
36 |
| The emerging link between cancer, metabolism, and circadian rhythms |
36 |
| Transcriptional regulation of macrophage cholesterol efflux and atherogenesis by a long noncoding RNA |
36 |
| Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma |
35 |
| Translation control of the immune checkpoint in cancer and its therapeutic targeting |
35 |
| Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition |
35 |
| Maternal IgA protects against the development of necrotizing enterocolitis in preterm infants |
35 |
| Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults |
34 |
| A case report of clonal EBV-like memory CD4(+) T cell activation in fatal checkpoint inhibitor-induced encephalitis |
34 |
| Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors |
34 |
| A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite |
34 |
| Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo |
34 |
| Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase |
34 |
| GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis |
33 |
| Tumor-educated B cells selectively promote breast cancer lymph node metastasis by HSPA4-targeting IgG |
33 |
| Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse |
33 |
| Platelet GPIb alpha is a mediator and potential interventional target for NASH and subsequent liver cancer |
33 |
